- Primary research
- Open Access
MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells
© The Author(s) 2016
- Received: 19 March 2015
- Accepted: 23 June 2016
- Published: 25 August 2016
Pancreatic cancer is currently one of the leading causes of cancer deaths without any effective therapies. Mir-145 has been found to be tumor-suppressive in various types of cancers. The aim of this study is to investigate the role of miR-145 in pancreatic cancer cells and explore its underlying mechanism.
Quantitative real time PCR was used to determine the expression level of miR-145 and angiopoietin-2 (Ang-2) mNRA, and the expression level of Ang-2 protein was measured by western blotting. The anti-cancer activities of miR-145 were tested both in in vitro by using cell invasion and colony formation assay and in vivo by using xenograft assay. The direct action of miR-145 on Ang-2 was predicted by TargetScan and confirmed by luciferase report assay. The vascularization of xenografts were performed by immunohistochemical analysis.
The expression level of miR-145 was significantly lower and the expression levels of Ang-2 mRNA and protein was significantly higher in the more aggressive pancreatic cancer cells (MiaPaCa-2 and Panc-1) when compared to that in BxPC3 cells. Overexpression of miR-145 in the BxPC3, MiaPaCa-2 and Panc-1 cells suppressed the cell invasion and colony formation ability, and the expression level of Ang-2 protein in MiaPaCa-2 and Panc-1 cells was also suppressed after pre-miR-145 transfection. Intratumoral delivery of miR-145 inhibited the growth of pancreatic cancer xenografts and angiogenesis in vivo, and also suppressed the expression level of angiopoietin-2 protein. Luciferase report assay showed that Ang-2 is a direct target of miR-145, and down-regulation of angiopoietin-2 by treatment with Ang-2 siRNA in the BxPC3, MiaPaCa-2 and Panc-1 cells suppressed cell invasion and colony formation ability. The reverse transcription PCR results also showed that Tie1 and Tie2 were expressed in BxPC3, MiaPaCa-2 and Panc-1 cells.
MiR-145 functions as a tumor suppressor in pancreatic cancer cells by targeting Ang-2 for translation repression and thus suppresses pancreatic cancer cell invasion and growth, which suggests that restoring of miR-145 may be a potential therapeutic target for pancreatic cancer.
- Pancreatic cancer
Pancreatic cancer was the fourth leading cause of cancer-related deaths and more than 45,000 new cases were estimated in 2013 . Recent studies showed that tumor suppressor loci were mutated or down-regulated in human pancreatic tumors, which accelerated tumor progression and resulted in invasive and metastatic malignancies . However, the role of tumor suppressors in pancreatic tumors are still largely unknown.
MicroRNAs (miRNAs) are a family of non-coding RNAs with a short length of 19–25 nucleotides. MiRNAs functioned as oncogene or tumour suppressor by binding to the 3′-untranslated region (UTR) of target genes to regulate their expression [3–5]. MiRNAs play an important role in many physiological and pathological processes, including in almost all aspects of cancer biology, such as cell proliferation, apoptosis, invasion/metastasis, and angiogenesis . Studies have shown that miR-145 has important implications in etiology, treatment and pathogenesis of cancer, including pancreatic cancers. Previous studies demonstrated the tumor suppressive role of miR-145 in caners, in which miR-145 suppressed liver and head and neck cancer cell invasion by targeting on ADAM metallopeptidase domain 17 [7, 8]. MiR-145 was also reported to repress pluripotency in human embryonic stem cells via regulating the expression of octamer-binding transcription factor 4, sex determining region Y-box 2 and Kruppel-like factor 4 . Moreover, in many other types of cancers, miR-145 and its direct target were also reported, for example, miR-145 directly targets AKT3 in thyroid cancer , and miR-145 also targets Mucin 1, cell surface associated in metastatic breast cancer , p70S6K1 in colon cancer , insulin-like growth factor receptor 1 in human bladder cancer cells , c-Myc in non-small cell lung cancer  and the transcription factor signal transducer and activator of transcription 1 in colon cancer . Recently, Khan et al.  reported that miR-145 targeted Mucin 13, cell surface associated to suppress growth and invasion of pancreatic cancer cells.
Angiopoietin-2 (Ang-2) is the ligand for an endothelial cell-specific tyrosine kinase receptor, and plays a key role in angiogenesis and tumor progression [17, 18]. Previous study reported that Ang-2 played a significant role in pancreatic carcinoma angiogenesis, and knockdown of Ang-2 induced anti-angiogenesis effect both in vitro and in vivo [19, 20]. Up to date, there is no evidence showing that expression of Ang-2 is linked with miRNAs in pancreatic cancers. In the present study, by using bioinformatics analytic tool (Targetscan), the 3′UTR of Ang-2 gene was found to be a target of miR-145. Here, we documented the tumor suppressive role of miR-145 in pancreatic cell lines. Subsequent analyses further established the relationship between miR-145 and Ang-2 in pancreatic cancer cells.
The human pancreatic cancer cells (MiaPaCa-2 and Panc-1) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies, Inc., Gaithersburg, MD) and BxPC-3 cells were cultured in RPMI-1640 medium (Life Technologies, Inc., Gaithersburg, MD), and both medium were supplemented with 10 % FBS (Life Technologies, Inc.) and 100 units/ml penicillin and 100 units/ml streptomycin. The BxPC-3, MiaPaCa-2 and Panc-1 cells were seeded to be 60–80 % confluent in 6-well plates 24 h before the cells were transfected with 30 pmol of either precursor of miR-145 (pre-miR-145; Ambion; P/N: AM17100, Product ID: PM11480) or scramble miRNA (Pre-miR™ miRNA Precursor Negative Control #1, P/N: AM17110); and angiopoietin-2 siRNA (siAng-2) or scramble (RiboBio, Guangzhou) using the Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Forty-eight hours after transfection, cells were processed for further experiments as described below.
In vitro invasion assay
The invasion assays in the pancreatic cancer cell lines were performed in a modified two-chamber assay. 2 × 105 cells were seeded on the upper chamber of 6-well Transwell plates (Costar; Cambridge, MA) coated with Matrigel (Becton–Dickinson, Heidelberg, Germany) diluted at a 1:2 ratio with medium and incubated for 24 h. The lower chamber was filled with DMEM containing 10 % FBS. After 24 h incubation, cells on the upper side of the membrane were wiped off and the membrane was fixed with 4 % paraformaldehyde and 0.25 % glutaraldehyde. Cells on the lower side of the membrane were stained with 0.5 % methylene blue in 50 % methanol and invaded cells were counted under a microscope. All invasion assays were done in triplicate.
Quantitative real-time PCR (qRT-PCR) analysis
Total RNA was extracted from cultured cells using TRIzol® reagent (Invitrogen). DNaseI-treated RNA was used for first strand cDNA synthesis using M-MLV reverse transcriptase (Promega) and oligo (dT) 15 according to the manufacture’s protocols and 1 μl cDNA samples were used for conventional PCR amplifications. QRT-PCR analysis was performed in a real-time PCR system (StepOne, Applied Biosystems) and the expression levels of Ang-2 were normalized to GAPDH determined by a SYBR Green-based comparative cycle threshold CT method. Real-time PCR primers were: Ang-2-F: 5′-AGA TTT TGG ACC AGA CCA GTG A-3′, Ang-2-R: 5′-GGA TGA TGT GCT TGT CTT CCA T-3′; GAPDH-F: 5′-TGT GGG CAT CAA TGG ATT TGG-3′, GAPDH-R: 5′-ACA CCA TGT ATT CCG GGT CAA T-3′; miR-145-F: 5′-AAG GGA GTC CAG TTT TCC CAG GAA TCC-3′, miR-145-R: 5′-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG AC-3′; U6-F: 5′-CTC GCT TCG GCA GCA CA-3′, U6-R: 5′-AAC GCT TCA CGA ATT TGC GT-3′.
The expression of Ang-2 was measured in pancreatic cancer cell lines (BxPC-3, MiaPaCa-2 and Panc-1) or tumor tissue by western blotting. Protein extraction was performed using the extraction buffer containing 10 mM Tris HCl (pH 7.5), 2 M urea, 2 mM EDTA, 2 mM EGTA, and protease inhibitors. Thirty micrograms of protein were loaded onto SDS–polyacrylamide gels, size fractionated on SDS-PAGE gels, and transferred to a nitrocellulose membrane using the semidry technique. The membranes were blocked with 5 % milk powder in TBST for 1 h. Specific monoclonal anti-Ang-2 (ab8452) and monoclonal anti-β-actin (ab3280) primary antibodies (Abcam Biotechnology, Cambridge, MA, USA) were used, and HRP conjugated immunoglobulin was used as a secondary antibody (Jackson ImmunoResearch Laboratories). West Pico Chemiluminescent (Pierce) was used as the substrate to visualize protein bands, which were quantified using densitometry image analysis software (Image Master VDS; Pharmacia Biotech). Normalization was made against β-actin expression.
Ang-2 concentrations in BxPC3, MiaPaCa-2 and Panc-1 cell culture supernatant were determined after transfection with pre-miR-145 for 48 h. Measurements were made with a commercially available enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, USA) according to the manufacturers’ instructions.
Soft agar assay
Colony formation and cell growth rate in soft agar were tested by plating 2.5 × 104 of BxPC3, MiaPaCa-2 and Panc-1 cells transfected with scramble or pre-miR-145 in 0.4 ml DMEM, supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, 100 g/ml amphotericin B, 3 % FBS, and 0.3 % low melting temperature agarose (Seaplaque) in 12-well plates (6 wells for each) coated with 0.8 ml 0.6 % low melting temperature agarose. Platelet-derived growth factor-bb (50 ng/ml) was added to half of the wells of each type of transfected cells. Colony formation was monitored for 5 days in 37 °C incubator, and colony number was counted under a microscope.
In vivo study
Female nude mice (4–6 weeks, 18–20 g) were purchased from the Model Animal Research Center of Nanjing University. 5 × 106 of Panc-1 cells (resuspended in 100 μl saline) were injected subcutaneously into the right flank of each mouse. Tumor volumes were determined every 5 days after injection as described previously . Mice with xenografts volume lager than 500 mm3 were treated with intratumoral injection of saline twice a week (saline group), scramble (saline plus scramble group) or pre-miR-145 (saline plus pre-miR-145 group) for 4 weeks. Each treatment group has eight animals. At the end of the experiment, mice were sacrificed and tumors were dissected for immunohistochemistry and western blot analysis. All the animal study was carried out in strict accordance with Institutional Animal Ethics Care and Use Committee of the Jiangsu Cancer Hospital (approved number 21040608). All surgery was performed under sodium pentobarbital anesthesia, and efforts were made to minimize suffering.
Immunohistochemical analysis of vascularization was performed using the analySIS system and the monoclonal antibody against Factor VIII (ab41186, abcam Biotechnology, Cambridge, MA, USA). Briefly, 5 µm thick FFPE sections were cut, placed on slides coated with 3-triethoxysilylpropylamine (Sigma, St. Louis, Missouri, USA), and then fixed overnight at 37 °C. After deparaffinization in xylene and rehydrating through graded alcohols, the slides were incubated in H2O2 to block endogenous peroxidase activity. Then sections were incubated with primary monoclonal antibody against Factor VIII (5 µg/ml) at 4 °C overnight. After overnight incubation, the sections were washed with PBS for 5 min × 3 times, and the sections were then incubated with biotinylated goat anti-rabbit immunoglobulin (dilution 1:300; Vector Laboratories, Burlingame, California, USA). The peroxidase activity was visualized by 3,3′-diaminobenzidine tetrahydrochloride. Hematoxylin was used as a counter stain.
The degree of vascularization was measured by the average number of Factor VIII-positive microvessels in three different areas at 200-fold magnification and recorded as microvessel density (MVD). Briefly, the Factor VIII stained sections were initially scanned at low power (100-fold magnification) and the areas having the highest number of microvessels were selected. Subsequently, microvessel counting was performed in three different areas at 200-fold magnification and the mean value was used for further analysis. Any clearly stained endothelial cells or cell clusters were considered as a single countable microvessel, regarding the presence of lumen and large vessels were automatically excluded from the analysis.
Constructs and luciferase assay
To determine whether Ang-2 is a downstream mediator of miR-145, the entire human Ang-2 3′-untranslated region (UTR) segment was amplified by PCR using mouse genomic DNA as a template. The PCR products were inserted into the p-MIR-report plasmid (Ambion). For luciferase reporter assay, 1 μg of firefly luciferase reporter plasmid, 0.5 μg of β-galactosidase expression vector (Ambion), and equal amount (200 pmol) of pre-miR-145 or scrambled negative control miRNA were transfected into cells in 6-well plates. The β-galactosidase vector was used as a transfection control. Twenty-four hours after transfection, cells were assayed using luciferase assay kits (Promega).
All results were expressed as mean ± SEM from at least three independent experiments. Significance analysis of normal distributed data were performed using two-tail Student’s t test, One-Way ANOVA, or Two-way ANOVA, as appropriate and P values of less than 0.05 were considered statistically significant.
The expression of miR-145 is reduced in more aggressive pancreatic cancer cell lines and accompanied with increased expression of Ang-2
MiR-145 suppressed cell invasion via decreasing the expression of Ang-2 in vitro
MiR-145 inhibited tumor growth and angiogenesis in vivo
MiR-145 directly regulated the expression of Ang-2 in pancreatic cancer cells
Antiangiogenic therapy targeting the vascular endothelial growth factor (VEGF) pathway has been considered as a standard cancer therapy strategy in the past decade [22, 23]. Ang-2-targeting therapies are now regarded as second-generation antiangiogenic drugs that combine with anti-VEGF to improve the hitherto limited clinical efficacy of established antiangiogenic therapy [24–26]. Recently, Ang-2 antibody treatment combines well with low-dose metronomic chemotherapy showed the effective anti-inflammatory and anti-angiogenic response of endothelial cells , provided a potential target of antiangiogenic drug development. We here reported that miR-145 suppressed the cell invasion via directly regulating the expression of Ang-2 in pancreatic cancer cells and ectopic expression of miR-145 inhibited tumor growth and angiogenesis in vivo. This study not only provided the information that Ang-2 may involve in pancreatic cancer cell invasion for the first time, but also provided a new strategy to develop antiangiogenic drug by targeting on miR-145.
The role of miR-145 in cancer have been extensively studied in various types of cancers. Most of the studies were focused on effect of miR-145 on cancer cell proliferation and metastasis. However, its role in tumor angiogenesis remains poorly defined. One study demonstrated miR-145 inhibited tumor angiogenesis and growth by neuroblastoma RAS and VEGF in breast cancers . The role of miR-145 on tumor angiogenesis is also found in osteosarcoma cells as well as colon cancer cells by targeting on VEGF and p70S6K1, respectively [12, 29]. Our study was consistent with previous studies showing the tumor suppressive roles in pancreatic cancer.
In the present study, we demonstrated that miR-145 suppressed cell invasion via directly regulating the expression of Ang-2 in pancreatic cancer. Ang-2 has been found to play an important role in angiogenesis and tumor progression. However, we also found that the mRNA expression level of Ang-2 in Panc-1 cells was significantly higher than that in MiaPaCa-2 cells; though there was no significant difference in Ang-2 protein levels between MiaPaCa-2 and Panc-1 cells. The possible reason could be that the difference of Ang-2 protein levels was very small and the semi-quantitative western blotting assay was not sensitive enough to detect the significant difference; and more sensitive assay be required in the future study. Recent study also showed that Ang-2 mediated beta-1-integrin activation as promoter of endothelial destabilization by enhancing β1-integrin-positive elongated matrix adhesions and actin stress fibers . Because of complexity of Ang-2 signaling pathway, its role still requires further investigation . Based on literature research and bioinformatics analysis (TargetScan), Ang-2 was predicted to be a down-stream mediator of miR-145. The present study showed Ang-2 is regulated by miR-145 in pancreatic cancer cells, which has been confirmed by examining the expressing levels of Ang-2 mRNA and protein as well as the luciferase report assay. As miR-145 have multiple targets, whether Ang-2 being specific for pancreatic cancer cell proliferation and invasion is still questionable. In the future study, we may restore the expression levels of Ang-2 to investigate the specific role of Ang-2 on tumor progression in pancreatic cancer. In addition, Ang-2 exerting its effect by interacting with Tie 1/2 receptor , but there is no evidence showing the existence of Tie 1/2 receptor in the pancreatic cancer cells. Therefore, it is necessary for us to determine the distribution and expression of these receptors in the future study, which may help us further understand the mechanistic action of Ang-2 in pancreatic cancer.
The study of miRNA-based therapies is still in its infancy. The first miRNA-based therapy specifically for cancer is using miRNA mimics or miRNA inhibitor, such as using synthetic miR-34a mimic loaded in liposomal nanoparticles to suppress liver cancer . Till now, the most advanced miRNA trial involves use of anti-miR-122 for hepatitis C therapy , which can reduce miR-122 expression by complementary binding to miR-122 sequence to lock nucleic acid structure. Meanwhile, several studies have focused on small-molecule compound’s modulation on microRNA expression. So far, the small-molecule modulators of miR-21, miR-122 and miR-34a have been identified with potent biologic activities [6, 35, 36].
In conclusion, our in vitro and in vivo studies suggest that miR-145 had a tumor suppressive effect on the pancreatic cancer cells. Therefore, miR-145 mimics or the small molecular modulators of miR-145 may provide the promising strategy to explore Ang-2 targeting antiangiogenic drugs in the future.
WH carried out further experiments for manuscript revision, and also revised the manuscript significantly. HC carried out the in vitro and in vivo studies and drafted the manuscript. OXL and NJS carried out the luciferase report assay. XSG and GH participated in the design of the study and performed the statistical analysis. ZJX conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
We thank Dr. Su from Southeast University (Nanjing, Jiangsu, China) for the kindly help on ELISA and immunohistochemistry techniques. This project was supported by the Science Development Program of Suzhou City, 2013 (Basic research for medical sciences and public health, Project No. SYSD2013033)
The authors declare that they have no competing interests.
All the animal study was carried out in strict accordance with Institutional Animal Ethics Care and Use Committee of the Jiangsu Cancer Hospital (approved number 21040608).
Informed consent was obtained from all individual participants included in the study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.View ArticlePubMedGoogle Scholar
- Hezel AF, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218–49.View ArticlePubMedGoogle Scholar
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.View ArticlePubMedGoogle Scholar
- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.View ArticlePubMedGoogle Scholar
- Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309(5740):1519–24.View ArticlePubMedGoogle Scholar
- Xiao Z, et al. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014;74(21):6236–47.View ArticlePubMedGoogle Scholar
- Yang XW, et al. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res. 2014;44(5):551–9.View ArticlePubMedGoogle Scholar
- Yu CC, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 2013;73(11):3425–40.View ArticlePubMedGoogle Scholar
- Xu N, et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–58.View ArticlePubMedGoogle Scholar
- Boufraqech M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517–31.View ArticlePubMedGoogle Scholar
- Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378–87.View ArticlePubMedGoogle Scholar
- Xu Q, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012;40(2):761–74.View ArticlePubMedGoogle Scholar
- Zhu Z, et al. MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett. 2014;588(17):3180–5.View ArticlePubMedGoogle Scholar
- Kavanagh T, et al. Process evaluation of appreciative inquiry to translate pain management evidence into pediatric nursing practice. Implement Sci. 2010;5:90.View ArticlePubMedPubMed CentralGoogle Scholar
- Gregersen LH, et al. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010;5(1):e8836.View ArticlePubMedPubMed CentralGoogle Scholar
- Khan S, et al. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 2014;5(17):7599–609.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009;11(2):111–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 2007;67(18):8429–32.View ArticlePubMedGoogle Scholar
- Zhou J, et al. Anti-angiogenesis by lentivirus-mediated small interfering RNA silencing of angiopoietin-2 gene in pancreatic carcinoma. Technol Cancer Res Treat. 2011;10(4):361–9.PubMedGoogle Scholar
- Zhang ZX, et al. Knockdown of angiopoietin-2 suppresses metastasis in human pancreatic carcinoma by reduced matrix metalloproteinase-2. Mol Biotechnol. 2013;53(3):336–44.View ArticlePubMedGoogle Scholar
- Xiao Z, et al. Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. Eur J Pharmacol. 2014;728:141–50.View ArticlePubMedGoogle Scholar
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.View ArticlePubMedPubMed CentralGoogle Scholar
- Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–74.View ArticlePubMedGoogle Scholar
- Holopainen T, et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst. 2012;104(6):461–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Kienast Y, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res. 2013;19(24):6730–40.View ArticlePubMedGoogle Scholar
- Koh YJ, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010;18(2):171–84.View ArticlePubMedGoogle Scholar
- Srivastava K, et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014;26(6):880–95.View ArticlePubMedGoogle Scholar
- Zou C, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012;11(11):2137–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Fan L, et al. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 2012;44(5):407–14.View ArticleGoogle Scholar
- Hakanpaa L, et al. Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat Commun. 2015;6:5962.View ArticlePubMedPubMed CentralGoogle Scholar
- Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med. 2012;2(9):a006550.View ArticlePubMedGoogle Scholar
- Singh N, et al. Angiotensin-(1-7) reverses angiogenic dysfunction in corpus cavernosum by acting on the microvasculature and bone marrow-derived cells in diabetes. J Sex Med. 2014;11(9):2153–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31(7):577.View ArticlePubMedGoogle Scholar
- Janssen HL, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–94.View ArticlePubMedGoogle Scholar
- Gumireddy K, et al. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 2008;47(39):7482–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Young DD, et al. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc. 2010;132(23):7976–81.View ArticlePubMedGoogle Scholar